Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot trial of Afamelanotide (SCENESSE) in patients with Hailey‐Hailey Disease (HHD, also known as familial benign pemphigus)

Trial Profile

Pilot trial of Afamelanotide (SCENESSE) in patients with Hailey‐Hailey Disease (HHD, also known as familial benign pemphigus)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afamelanotide (Primary)
  • Indications Pemphigus
  • Focus Therapeutic Use
  • Acronyms CUV010
  • Most Recent Events

    • 18 Jul 2016 Results from this study published in both the New England Journal of Medicine and Photochemisty and Photobiology in 2009, as per Clinuvel Pharmaceuticals media release.
    • 02 Dec 2013 New trial record
    • 28 Oct 2013 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top